Last reviewed · How we verify

NCT05463393

Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients

Suspended EARLY_PHASE1 Last updated 1 July 2025
What this trial tests

EARLY_PHASE1 trial testing Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/ in COVID-19 Respiratory Infection in 50 participants. Suspended.

Timeline
1 October 2020
Primary endpoint
30 January 2022
31 December 2025

Quick facts

Lead sponsorMedical University of Lublin
PhaseEARLY_PHASE1
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingsingle
Primary purposetreatment
Enrollment50
Start date1 October 2020
Primary completion30 January 2022
Estimated completion31 December 2025
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Lublin

Who can join

18 and older, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been well documented that coronavirus COVID-19 disease is associated with massive inflammatory response and cytokine storm. Several medications have been used to ameliorate COVID-19-related inflammation. Xanthohumol, a natural medication extracted from hop cones, possesses strong anti-inflammatory properties and can reduce the severity of inflammatory response. The aim of this study is to analyze the effect of Xanthohumol on clinical course, inflammatory response and outcome in patients admitted to the ICU due to COVID-related acute respiratory failure with an oxygenation index (PaO2/FiO2) less than 150.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients.
    Dabrowski W, Gagos M, Siwicka-Gieroba D, Piechota M, et al · · 2023 · cited 10× · PMID 36508996 · DOI 10.1016/j.biopha.2022.114082
  2. Advancing Brain Health Naturally: β-Caryophyllene and Xanthohumol as Neuroprotective Agents.
    Ivanova S, Dzhakova Z, Todorova V, Boyuklieva R, et al · · 2025 · cited 1× · PMID 41011595 · DOI 10.3390/molecules30183702

Verify or expand the search:

Other recruiting trials for COVID-19 Respiratory Infection

Currently open trials in the same condition.

Other Medical University of Lublin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing